Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Baselga J, et al. Among authors: van dam p. J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20. J Clin Oncol. 2009. PMID: 19380449 Clinical Trial.
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, Van de Velde H, Vinken P, Vermeulen PB, Van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY. Trinh XB, et al. Among authors: van dam pa, van laere sj, van de velde h. Oncol Rep. 2012 Mar;27(3):657-63. doi: 10.3892/or.2011.1562. Epub 2011 Nov 24. Oncol Rep. 2012. PMID: 22134540 Clinical Trial.
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Bertucci F, et al. Among authors: van laere sj, van dam p. Ann Oncol. 2014 Feb;25(2):358-65. doi: 10.1093/annonc/mdt496. Epub 2013 Dec 2. Ann Oncol. 2014. PMID: 24299959 Free PMC article.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. Mayer IA, et al. Among authors: van dam pa. Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5. Clin Cancer Res. 2019. PMID: 30723140 Free PMC article. Clinical Trial.
Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node.
Van den Eynden GG, Vandenberghe MK, van Dam PJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Van den Eynden GG, et al. Among authors: van dam p, van dam pj, van marck ea. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5391-7. doi: 10.1158/1078-0432.CCR-07-1230. Clin Cancer Res. 2007. PMID: 17875768 Free article.
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.
Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D. Schettini F, et al. Cancers (Basel). 2021 Sep 1;13(17):4421. doi: 10.3390/cancers13174421. Cancers (Basel). 2021. PMID: 34503231 Free PMC article. Review.
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Van Laere SJ, et al. Among authors: van den eynden gg, van dam p, van der auwera i, van marck ea. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56. doi: 10.1158/1078-0432.CCR-05-2800. Clin Cancer Res. 2006. PMID: 16740744
404 results